New York, New York 10021

  • Myelodysplastic/Myeloproliferative Neoplasms


RATIONALE: CC-5013 may stop the growth of myelodysplastic syndrome by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of CC-5013 in treating patients who have transfusion-dependent low-risk or intermediate-risk myelodysplastic syndrome.

Study summary:

OBJECTIVES: Primary - Determine the efficacy of CC-5013, in terms of hematopoietic improvement, in patients with transfusion-dependent low- or intermediate-1-risk myelodysplastic syndromes. Secondary - Determine the safety of this drug in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive oral CC-5013 once daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 136 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Diagnosis of low- or intermediate-1-risk myelodysplastic syndromes (MDS) - No abnormality of chromosome 5 involving a deletion between bands q31 and q33 - Red blood cell (RBC) transfusion-dependent, defined as having received at least 2 units of RBCs within the past 8 weeks - No proliferative (WBC ≥ 12,000/mm^3) chronic myelomonocytic leukemia PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - Not specified Hematopoietic - See Disease Characteristics - Absolute neutrophil count ≥ 500/mm^3 - Platelet count ≥ 50,000/mm^3 - No clinically significant anemia due to iron, B_12, or folate deficiencies, autoimmune or hereditary hemolysis, or gastrointestinal bleeding* NOTE: *If a marrow aspirate is not evaluable for storage iron, transferrin saturation must be ≥ 20% AND ferritin ≥ 50 ng/mL Hepatic - AST and ALT ≤ 3.0 times upper limit of normal - Bilirubin ≤ 2.0 mg/dL Renal - Creatinine ≤ 2.5 mg/dL Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No prior grade 3 or greater allergic reaction or hypersensitivity to thalidomide - No prior grade 3 or greater rash or any desquamation while taking thalidomide - No other malignancy within the past 3 years except basal cell or squamous cell cancer or carcinoma in situ of the cervix or breast - No other serious medical condition, laboratory abnormality, or psychiatric illness that would preclude giving informed consent or participating in the study - Able to aspirate bone marrow PRIOR CONCURRENT THERAPY: Biologic therapy - No prior CC-5013 - More than 7 days since prior hematopoietic growth factors - No concurrent red blood cell hematopoietic growth factors (e.g., epoetin alfa) Chemotherapy - More than 28 days since prior chemotherapy for MDS - No concurrent chemotherapy for MDS Endocrine therapy - More than 28 days since prior chronic use (more than 2 weeks) of more than physiologic doses of corticosteroids (dose equivalent to more than 10 mg/day of prednisone) - No concurrent corticosteroids except steroids for adrenal failure, hormones for non-cancer-related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic - No concurrent androgens Radiotherapy - Not specified Surgery - Not specified Other - More than 28 days since prior standard (i.e., immunosuppressive or cytoprotective agents) therapy for MDS - More than 28 days since prior experimental therapy - No other concurrent investigational agents



Primary Contact:

Study Chair
Virginia Klimek, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.